Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ipilimumab + Nivolumab & Hepatocellular Carcinoma (HCC), Ipilimumab + nivolumab is FDA‑approved for hepatocellular carcinoma, but there is no EMA approval for this combination in HCC as of 2026 (1, 2, 4)
With regard to second-line therapy, nivolumab + ipilimumab reached an ORR of 32%, and pembrolizumab alone resulted in an ORR of 17% among sorafenib-experienced patients with advanced Hepatocellular Carcinoma (HCC) (6). Ipilimumab + nivolumab or [ipilimumab + pembrolizumab](b…